Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy

Atlas-M Study Group

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)1949-1954
Number of pages6
JournalJournal of Antimicrobial Chemotherapy
Volume73
Issue number7
DOIs
Publication statusPublished - Jul 1 2018

Keywords

  • atazanavir
  • biological marker
  • C reactive protein
  • D dimer
  • interleukin 6
  • lamivudine
  • ritonavir
  • adult
  • Article
  • blood sampling
  • CD4 lymphocyte count
  • clinical outcome
  • comparative study
  • controlled study
  • enzyme linked immunosorbent assay
  • female
  • human
  • Human immunodeficiency virus 1
  • Human immunodeficiency virus 1 infection
  • Human immunodeficiency virus infected patient
  • limit of detection
  • maintenance therapy
  • major clinical study
  • male
  • medical history
  • mortality
  • nonhuman
  • randomized controlled trial
  • treatment duration
  • virus load

Cite this

@article{8fea145a4c9a416185fea989045a5da3,
title = "Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy",
keywords = "atazanavir, biological marker, C reactive protein, D dimer, interleukin 6, lamivudine, ritonavir, adult, Article, blood sampling, CD4 lymphocyte count, clinical outcome, comparative study, controlled study, enzyme linked immunosorbent assay, female, human, Human immunodeficiency virus 1, Human immunodeficiency virus 1 infection, Human immunodeficiency virus infected patient, limit of detection, maintenance therapy, major clinical study, male, medical history, mortality, nonhuman, randomized controlled trial, treatment duration, virus load",
author = "S. Belmonti and F. Lombardi and E. Quiros-Roldan and A. Latini and A. Castagna and A. Borghetti and G. Baldin and A. Ciccullo and R. Cauda and {De Luca}, A. and {Di Giambenedetto}, S. and {Atlas-M Study Group}",
note = "Cited By :1 Export Date: 10 January 2019 CODEN: JACHD Correspondence Address: Lombardi, F.; Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart of RomeItaly; email: francesca.lombardi@gmail.com Chemicals/CAS: atazanavir, 198904-31-3; C reactive protein, 9007-41-4; lamivudine, 134678-17-4, 134680-32-3; ritonavir, 155213-67-5 References: Abgrall, S., Ingle, S.M., May, M.T., Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe andNorth America 2002-2009 (2013) AIDS, 27, pp. 803-813; Margolis, A.M., Heverling, H., Pham, P.A., A review of the toxicity of HIV medications (2014) JMedToxicol, 10, pp. 26-39; Di Giambenedetto, S., Fabbiani, M., Quiros Roldan, E., Treatment simplification to atazanavir/ritonavir ! lamivudine versus maintenance of atazanavir/ritonavir ! two NRTIs in virologically suppressed HIV-1-infected patients:. week results from a randomized trial (ATLAS-M) (2017) J Antimicrob Chemother, 72, pp. 1163-1171; Perez-Molina, J.A., Rubio, R., Rivero, A., Dual treatment with atazanavirritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial (2015) Lancet Infect Dis, 15, pp. 775-784; Neuhaus, J., Jacobs, D.R., Jr., Baker, J.V., Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection (2010) J Infect Dis, 201, pp. 1788-1795; Wada, N.I., Jacobson, L.P., Margolick, J.B., The effect of HAART-induced HIV suppression on circulatingmarkers of inflammation and immune activation (2015) AIDS, 29, pp. 463-471; Boulware, D.R., Hullsiek, K.H., Puronen, C.E., Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death (2011) J Infect Dis, 203, pp. 1637-1646; Freiberg, M.S., Bebu, I., Tracy, R., D-dimer levels before HIV seroconversion remain elevated even after viral suppression and are associated with an increased risk of non-AIDS events (2016) PLoS One, 11; Sandler, N.G., Wand, H., Roque, A., Plasma levels of soluble CD14 independently predict mortality in HIV infection (2011) J Infect Dis, 203, pp. 780-790; Tenorio, A.R., Zheng, Y., Bosch, R.J., Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment (2014) J Infect Dis, 210, pp. 1248-1259; Wada, N.I., Bream, J.H., Mart{\'i}nez-Maza, O., Inflammatory biomarkers and mortality risk among HIV-suppressed men: a multisite prospective cohort study (2016) Clin Infect Dis, 63, pp. 984-990; Hileman, C.O., Funderburg, N.T., Inflammation, immuneactivation, and antiretroviral therapy in HIV (2017) Curr HIV/AIDS Rep, 14, pp. 93-100; Lombardi, F., Belmonti, S., Quiros-Roldan, E., Evolution of bloodassociated HIV-1 DNA levels after 48weeks of switching to atazanavir/ritonavir! lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial (2017) JAntimicrobChemother, 72, pp. 2055-2059; Sabin, C.A., Worm, S.W., Weber, R., Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration (2008) Lancet, 371, pp. 1417-1426; Torres, B., Guardo, A.C., Leal, L., Protease inhibitormonotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation (2014) J IntAIDS Soc, 17, p. 19246; Eastburn, A., Scherzer, R., Zolopa, A.R., Association of low level viremia with inflammation and mortality in HIV-infected adults (2011) PLoS One, 6; Chun, T.W., Murray, D., Justement, J.S., Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy (2011) J InfectDis, 204, pp. 135-138; Falasca, F., Di Carlo, D., De Vito, C., Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns (2017) BMC Infect Dis, 17, p. 581; Mart{\'i}nez, E., Larrousse, M., Podzamczer, D., Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction (2010) AIDS, 24, pp. F1-F9; Martin, A., Amin, J., Cooper, D.A., Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial (2010) AIDS, 24, pp. 2657-2663; Sutherland, J.P., McKinley, B., Eckel, R.H., Themetabolic syndrome and inflammation (2004) Metab Syndr Relat Disord, 2, pp. 82-104",
year = "2018",
month = "7",
day = "1",
doi = "10.1093/jac/dky125",
language = "English",
volume = "73",
pages = "1949--1954",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy

AU - Belmonti, S.

AU - Lombardi, F.

AU - Quiros-Roldan, E.

AU - Latini, A.

AU - Castagna, A.

AU - Borghetti, A.

AU - Baldin, G.

AU - Ciccullo, A.

AU - Cauda, R.

AU - De Luca, A.

AU - Di Giambenedetto, S.

AU - Atlas-M Study Group

N1 - Cited By :1 Export Date: 10 January 2019 CODEN: JACHD Correspondence Address: Lombardi, F.; Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart of RomeItaly; email: francesca.lombardi@gmail.com Chemicals/CAS: atazanavir, 198904-31-3; C reactive protein, 9007-41-4; lamivudine, 134678-17-4, 134680-32-3; ritonavir, 155213-67-5 References: Abgrall, S., Ingle, S.M., May, M.T., Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe andNorth America 2002-2009 (2013) AIDS, 27, pp. 803-813; Margolis, A.M., Heverling, H., Pham, P.A., A review of the toxicity of HIV medications (2014) JMedToxicol, 10, pp. 26-39; Di Giambenedetto, S., Fabbiani, M., Quiros Roldan, E., Treatment simplification to atazanavir/ritonavir ! lamivudine versus maintenance of atazanavir/ritonavir ! two NRTIs in virologically suppressed HIV-1-infected patients:. week results from a randomized trial (ATLAS-M) (2017) J Antimicrob Chemother, 72, pp. 1163-1171; Perez-Molina, J.A., Rubio, R., Rivero, A., Dual treatment with atazanavirritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial (2015) Lancet Infect Dis, 15, pp. 775-784; Neuhaus, J., Jacobs, D.R., Jr., Baker, J.V., Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection (2010) J Infect Dis, 201, pp. 1788-1795; Wada, N.I., Jacobson, L.P., Margolick, J.B., The effect of HAART-induced HIV suppression on circulatingmarkers of inflammation and immune activation (2015) AIDS, 29, pp. 463-471; Boulware, D.R., Hullsiek, K.H., Puronen, C.E., Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death (2011) J Infect Dis, 203, pp. 1637-1646; Freiberg, M.S., Bebu, I., Tracy, R., D-dimer levels before HIV seroconversion remain elevated even after viral suppression and are associated with an increased risk of non-AIDS events (2016) PLoS One, 11; Sandler, N.G., Wand, H., Roque, A., Plasma levels of soluble CD14 independently predict mortality in HIV infection (2011) J Infect Dis, 203, pp. 780-790; Tenorio, A.R., Zheng, Y., Bosch, R.J., Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment (2014) J Infect Dis, 210, pp. 1248-1259; Wada, N.I., Bream, J.H., Martínez-Maza, O., Inflammatory biomarkers and mortality risk among HIV-suppressed men: a multisite prospective cohort study (2016) Clin Infect Dis, 63, pp. 984-990; Hileman, C.O., Funderburg, N.T., Inflammation, immuneactivation, and antiretroviral therapy in HIV (2017) Curr HIV/AIDS Rep, 14, pp. 93-100; Lombardi, F., Belmonti, S., Quiros-Roldan, E., Evolution of bloodassociated HIV-1 DNA levels after 48weeks of switching to atazanavir/ritonavir! lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial (2017) JAntimicrobChemother, 72, pp. 2055-2059; Sabin, C.A., Worm, S.W., Weber, R., Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration (2008) Lancet, 371, pp. 1417-1426; Torres, B., Guardo, A.C., Leal, L., Protease inhibitormonotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation (2014) J IntAIDS Soc, 17, p. 19246; Eastburn, A., Scherzer, R., Zolopa, A.R., Association of low level viremia with inflammation and mortality in HIV-infected adults (2011) PLoS One, 6; Chun, T.W., Murray, D., Justement, J.S., Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy (2011) J InfectDis, 204, pp. 135-138; Falasca, F., Di Carlo, D., De Vito, C., Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns (2017) BMC Infect Dis, 17, p. 581; Martínez, E., Larrousse, M., Podzamczer, D., Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction (2010) AIDS, 24, pp. F1-F9; Martin, A., Amin, J., Cooper, D.A., Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial (2010) AIDS, 24, pp. 2657-2663; Sutherland, J.P., McKinley, B., Eckel, R.H., Themetabolic syndrome and inflammation (2004) Metab Syndr Relat Disord, 2, pp. 82-104

PY - 2018/7/1

Y1 - 2018/7/1

KW - atazanavir

KW - biological marker

KW - C reactive protein

KW - D dimer

KW - interleukin 6

KW - lamivudine

KW - ritonavir

KW - adult

KW - Article

KW - blood sampling

KW - CD4 lymphocyte count

KW - clinical outcome

KW - comparative study

KW - controlled study

KW - enzyme linked immunosorbent assay

KW - female

KW - human

KW - Human immunodeficiency virus 1

KW - Human immunodeficiency virus 1 infection

KW - Human immunodeficiency virus infected patient

KW - limit of detection

KW - maintenance therapy

KW - major clinical study

KW - male

KW - medical history

KW - mortality

KW - nonhuman

KW - randomized controlled trial

KW - treatment duration

KW - virus load

U2 - 10.1093/jac/dky125

DO - 10.1093/jac/dky125

M3 - Article

VL - 73

SP - 1949

EP - 1954

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 7

ER -